Synermore Biologics (Suzhou) Co Ltd, a biopharmaceutical company in SIP, recently received the approval from the National Medical Products Administration (NMPA) for piloting segmented production of its Zamerovimab and Mazorelvimab Injection. The company is the second pilot site for segmented production of biologics in East China’s Jiangsu province, following Suzhou Suncadia Biopharmaceuticals Co Ltd, and the product is the second product from SIP to come into segmented production.
Segmented production of biologics is a manufacturing approach where the production process of biologics is divided into several stages, with each stage potentially being outsourced to a different contract manufacturing organization. It marks significant progress in optimizing resource allocation, reducing production cost and improving production efficiency.
Synermore was founded in SIP’s BioBAY in 2016. It is dedicated to developing and manufacturing innovative monoclonal antibody drugs and biosimilars for the treatment of malignant tumors, infectious diseases and autoimmune diseases.
The Zamerovimab and Mazorelvimab Injection was approved for market launch in June 2024 as China’s first anti-rabies antibody cocktail therapy that aligns with the World Health Organization (WHO) recommendations.
January 13, 2026
